The present application provides novel isolated and purified polynucleotides and polypeptides related to interleukin－13 (IL－13) antagonists, such as antibodies and/or antigen－binding fragments thereof, that specifically bind to IL－13 and reduce, neutralize, and/or antagonize at least one IL－13－associated activity. The present application also provides methods for modulating the interaction between IL－13 and its receptor, or subunits, thereof. The present application also is directed to novel methods for diagnosing, prognosing, monitoring the progress of, and treating IL－13－associated disorders (e.g., respiratory disorders, inflammatory and/or autoimmune conditions, viral infection, cancers, and suppression of type 1 immune responses). The present application is further directed to novel therapeutics and therapeutic targets and to methods of screening and assessing test compounds for the intervention (treatment) and prevention of said IL－13－associated disorders.本申請案提供與白介素－13(IL－13)拮抗劑相關之新穎經分離且純化的多核苷酸及多肽類，諸如：特異結合IL－13並降低、中和及/或拮抗至少一種與IL－13相關之活性的抗體及/或其抗原結合片段。本申請案亦提供用於調節IL－13與其受體或彼之次單位間之交互作用的方法。本申請案亦關於用於診斷、判斷預後、監控與IL－13相關病症之進展及治療與IL－13相關病症之方法(該IL－13相關病症係例如：呼吸病症、發炎及/或自體免疫病況、病毒感染、癌症及壓抑第1型免疫反應)。本申請案進一步關於新穎之治療劑和治療靶的以及篩選並評估用於介入(治療)和預防該IL－13相關病症之測試化合物的方法。
